OY3

OY3 is a small-molecule autophagosome-tethering compound (ATTEC) designed to treat atherosclerosis and hypercholesterolemia by inducing the targeted degradation of proprotein convertase subtilisin/kexin type-9 (PCSK9). Developed by researchers at Fudan University and East China University of Science and Technology, OY3 functions as a bifunctional degrader that simultaneously binds to PCSK9 and the autophagosome-associated protein LC3. This recruitment facilitates the transport of PCSK9 into autophagosomes for subsequent lysosomal degradation. Preclinical studies in mouse models have demonstrated that OY3 significantly lowers plasma low-density lipoprotein cholesterol (LDL-C) levels and alleviates atherosclerotic symptoms, showing greater potency than simvastatin at equivalent doses. Furthermore, OY3 counteracts the compensatory upregulation of PCSK9 typically induced by statin therapy, suggesting its potential as a synergistic combination treatment to enhance lipid-lowering efficacy.

Other names

PCSK9-ATTEC OY3PCSK-9-ATTEC OY3PCSK 9-ATTEC OY3